Healthcare Stock Jumps 4% After SBI and HDFC Mutual Funds Increase Stake in the Company

Synopsis: A healthcare stock surged around 4 percent after SBI Mutual Fund and HDFC Mutual Fund acquired significant shares through a block deal following a major stake sale by a private equity-backed investor.

The share of this company, which operates several US FDA-approved manufacturing facilities in India (Vadodara, Baddi, Panelav) and has a strong R&D focus, gained investor traction after announcing a stake acquisition by DII.

With a market capitalization of Rs 37,820 crore, Anthem Biosciences Ltd’s share made a day high of Rs 686.70 per share, up by 4 percent from its previous day’s close price of Rs 660 per share. The share of this company has given a negative return of 11 percent since its listing in July 2025.

News

Viridity Tone LLP, backed by the private equity firm True North, has sold a 3.6 percent stake in Anthem Biosciences through open-market transactions worth about Rs 1,262 crore. The firm sold around 2.03 crore shares at Rs 621.11 per share, slightly below the stock’s closing market price.

The shares were mainly purchased by institutional investors, including SBI Mutual Fund and HDFC Mutual Fund, indicating continued interest from large investors. Despite the stake sale, Anthem Biosciences’ stock recovered from its intraday low and ended the day only slightly lower, showing resilient investor sentiment.

SBI Mutual Fund and HDFC Mutual Fund bought shares sold by Viridity Tone in Anthem. SBI MF acquired 32.26 lakh shares (0.57 percent) for Rs 200.36 crore, while HDFC MF purchased 60.75 lakh shares (1.08 percent) worth Rs 377.3 crore at Rs 621.1 per share.

As of December 2025, the promoter stake remained unchanged at 74.69 percent. Foreign institutional investors slightly reduced their holdings from 1.66 percent in Q2 FY26 to 1.37 percent in Q3 FY26. Meanwhile, domestic institutional investors increased their stake from 7.21 percent to 7.60 percent, while public shareholding edged down marginally from 16.42 percent to 16.34 percent quarter-on-quarter.

Anthem Biosciences Limited, established in 2006 and headquartered in Bengaluru, is a leading, innovation-driven Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in drug discovery, development, and commercial manufacturing for global pharmaceutical and biotech companies.It is a premier integrated CRDMO in India, specializing in both New Chemical Entities (NCEs) and New Biological Entities

Financial Highlights: The revenue from operations declined by 15 percent to Rs 423 crore in Q3 FY26 from Rs 498 crore in Q3 FY25, and EBIDT fell by 1 percent to Rs 157 crore in Q3 FY26 from Rs 160 crore in Q3 FY25. Accompanied by a net profit decline of 11 percent to Rs 92.8 crore in Q3 FY26 from Rs 124 crore in Q3 FY25, resulting in an EPS decline of 26 percent to Rs 1.65 per share in Q3 FY26.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Healthcare Stock Jumps 4% After SBI and HDFC Mutual Funds Increase Stake in the Company appeared first on Trade Brains.